Moderna, Inc.’s Stock Price Drops to $42.05, Seeing a Notable 3.69% Decrease

Moderna, Inc. (MRNA)

42.05 USD -1.61 (-3.69%) Volume: 7.15M

Moderna, Inc.’s stock price stands at 42.05 USD, experiencing a dip of -3.69% this trading session with a trading volume of 7.15M. With a significant YTD decline of -57.72%, MRNA’s stock performance continues to be a focal point in the market.

Latest developments on Moderna, Inc.

Despite recent fluctuations, Moderna (MRNA) remains optimistic about its future, with its stock jumping 7.5% in one day. Analysts have lowered the price target to $45 from $59 at JPMorgan, but Moderna Inc. continues to outperform competitors. The company’s shares surged amid promising vaccine developments, showcasing its resilience in the market. Citigroup Inc. recently purchased a significant number of Moderna shares, indicating confidence in the company’s potential. Moderna is set to present at upcoming conferences in December 2024, further solidifying its position in the healthcare sector.

Moderna, Inc. on Smartkarma

Analysts at Baptista Research on Smartkarma have published two reports on Moderna Inc. with a bullish outlook. In the first report titled “Moderna Inc.: Expanding Global Presence For Unmatched Impact! – Major Drivers,” the analysts highlighted the company’s strong financial position, with $1.9 billion in revenue and $9.2 billion in cash and investments for the third quarter of 2024. This solid liquidity provides Moderna with a strong foundation for future initiatives.

In the second report titled “Moderna Inc.: These Are The 4 Biggest Challenges That Bears Are Counting On! – Major Drivers,” the analysts discussed Moderna’s recent Quarterly Earnings performance, noting advancements in the company’s respiratory vaccine portfolio, including the COVID-19 vaccine mRNA-1273 and the new RSV vaccine mRESVIA. The analysts emphasized the significance of mRNA-1273 in combating COVID-19, with substantial hospitalization rates reported for the ’23/’24 season by the CDC.

A look at Moderna, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Moderna, Inc. operates as a biotechnology company that focuses on the discovery and development of messenger RNA therapeutics and vaccines. The company has received a high score of 4 for its overall value, indicating a positive long-term outlook in terms of its market value and potential for growth.

While Moderna has a low score of 1 for dividends and moderate scores of 2 for growth and momentum, it has scored a 3 for resilience. This suggests that the company may have a stable foundation and ability to withstand market fluctuations, which could bode well for its future prospects in the biotechnology sector.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma